{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00937",
      "entity_text" : "CSF LRRK2",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-0079" ],
      "Organ" : [ "uberon:UBERON:0000105" ]
    }
  },
  "verbose_text" : "Finally, using this methodology we showed that PD patients harboring the G2019S LRRK2 mutation have significantly higher CSF LRRK2 levels compared to healthy individuals, sporadic PD patients, and non manifesting LRRK2 carriers.",
  "reading_complete" : "2020-08-05T19:58:52Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T19:57:38Z",
  "trigger" : "levels",
  "evidence" : [ "CSF LRRK2 levels" ],
  "pmc_id" : "7262382",
  "score" : 0
}